Over the past week, LMC Healthcare & Centricity Research have been in attendance at the 2018 American Diabetes Association’s 78th Scientific Sessions, at the Orange County Convention Center in Orlando, Florida!

Chief Medical Officer Dr. Ronnie Aronson was selected to highlight the study  “First Assessment of the Performance of an Implantable CGM System through 180 Days in a Primarily Adolescent Population with Type 1 Diabetes,” in the official Press Program for ADA. Dr. Aronson’s study was selected based on its overall excellence in furthering research and treatment for people with diabetes, as well as its potential appeal to the medical/scientific and general news media.

During this Press Program, more than 200 journalists and reporters from around the world were present for this special presentation, and have began to share more details in various news outlets.

“We were very pleased by the accuracy of the CGM system—it had a MARD comparable to other more- established CGM systems,” said lead study author Ronnie Aronson, MD, FRCPC, FACE, endocrinologist and chief medical officer of LMC Diabetes & Endocrinology in Canada. “We were also impressed with the stability of the life span of the sensor, which showed no significant decline in accuracy from day 60 to days 90 and 180. Additionally, given the pediatric population that we were largely studying, we were impressed by the rapidity with which CGM use became an integral part of their family life. These teens were athletic for the most part, and were particularly appreciative that both the implanted sensor and the wearable transmitter weren’t affected by their athletic gear. The adolescents’ parents expressed their own appreciation at their new ability to be more aware of their children’s glucose levels. Use of a continuous glucose sensor can have significant implications for a patient’s ability to provide optimal self-care, and awareness of their glucose trends allows patients to adjust their insulin delivery, whether by injections or pump, to better match the child’s actual needs. While we were not attempting to manage the patients’ blood glucose levels with the device in our study, the awareness of their glucose levels allowed them to spontaneously achieve a better HbA1c over time.”

To read more about Dr. Aronson’s study presentation, and the 180-day implantable CGM study, please follow the links below:

Article & Video: MDedge – Eversense CGM shown safe, accurate for 180 days in adolescents

Article: The National Post – Research and innovation leading to better outcomes for Canadians living with diabetes

Article: MedPage Today – 180-Day Implantable CGM Deemed Safe in T1D Patients

Article: Healio Endocrine Today –  6-month implantable CGM safe, accurate in teens, adults

Article: Markets Insider – Fully Implantable, Continuous Glucose Monitoring Sensor Provided Accuracy for Six Months in Adolescents and Adults with Type 1 Diabetes

*Note: articles will continue to be added above as they are released